GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Archives for Antunes S

Vaccination with proteins involved in tick-pathogen interactions reduces vector infestations and pathogen infection

  • Authors: Antunes S, de la Fuente J, Domingos A, Merino O, Moreno-Cid JA, Mosqueda J, Perez de la Lastra JM, Rodríguez S, Rosario-Cruz R
  • Publication Year: 2013
  • Journal: Vaccine
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/24084474

Tick-borne pathogens cause diseases that greatly impact animal health and production worldwide. The ultimate goal of tick vaccines is to protect against tick-borne diseases through the control of vector infestations and reducing pathogen infection and transmission. Tick genetic traits are involved in vector-pathogen interactions and some of these molecules such as Subolesin (SUB) have been shown to protect against vector infestations and pathogen infection.
Read More

Functional genomics studies of Rhipicephalus (Boophilus) annulatus ticks in response to infection with the cattle protozoan parasite, Babesia bigemina.

  • Authors: Almazán C, Antunes S, de la Fuente J, Do Rosário V, Domingos A, Galindo RC, Golovchenko M, Grubhoffer L, Rudenko N, Shkap V
  • Journal: International Journal for Parasitology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Functional+genomics+studies+of+Rhipicephalus+(Boophilus)+annulatus+ticks+in+response+to+infection+with+the+cattle+protozoan+parasite%2C+Babesia+bigemina

Ticks are obligate haematophagous ectoparasites of wild and domestic animals as well as humans, considered to be second worldwide to mosquitoes as vectors of human diseases, but the most important vectors of disease-causing pathogens in domestic and wild animals. Babesia spp. are tick-borne pathogens that cause a disease called babesiosis in a wide range of animals and in humans.
Read More

Toward the discovery of inhibitors of babesipain-1, a Babesia bigemina cysteine protease: In vitro evaluation, homology modeling and molecular docking studies

  • Authors: Antunes S, Domingos A, Gomes JRB, Gomes P, Gonçalves LM, Perez B, Teixeira C
  • Journal: Journal of Computer-aided Molecular Design
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/24129820

Babesia bigemina is a protozoan parasite that causes babesiosis, a disease with a world-wide distribution in mammals, principally affecting cattle and man. The unveiling of the genome of B. bigemina is a project in active progress that has already revealed a number of new targets with potential interest for the design of anti-babesiosis drugs. In this context, babesipain-1 has been identified as a proteolytically active enzyme whose three-dimensional structure has not been resolved yet, but which is known to be inhibited by cysteine proteases inhibitors such as E64, ALLN, leupeptin, and vinyl sulfones
Read More

Generation of an antibody that recognizes Plasmodium chabaudi cysteine protease (chabaupain-1) in both sexual and asexual parasite life cycle and evaluation of chabaupain-1 vaccine potential

  • Authors: Almeida AJ, Antunes S, Armada A, Custodio A, Domingos A, Gazarini M, Gonçalves LM, Rodrigues A, Rosário VE, Santos-Gomes G, Silveira H
  • Publication Year: 2013
  • Journal: Experimental Parasitology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23830988

Malaria cysteine proteases have been shown to be immunogenic and are being exploited as serodiagnostic markers, drug and vaccine targets. Several Plasmodium spp. cysteine proteases have been described and the best characterized of these are the falcipains, a family of papain-family enzymes. Falcipain-2 and falcipain-3 act in concert with other proteases to hydrolyze host erythrocyte hemoglobin in the parasite food vacuole.
Read More

Prevalence and genetic diversity of Babesia and Anaplasma species in cattle in Sudan

  • Authors: Antunes S, Awad H, de la Fuente J, Do Rosário VE, Domingos A, El Hussein AM, Galindo RC
  • Journal: Veterinary Parasitology
  • Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=19&SID=P2WA5hwy5j35Sqjoq2z&page=1&doc=1

Disease prevalence studies are one of the most valuable tools to demonstrate the risk or impact of certain infections in local and global economies. The data obtained in these studies contribute to develop strategies for disease control.
Read More

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok